TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability

Sha Zhou

Sun Yat-sen University Cancer Center

Jianhong Peng

Sun Yat-sen University Cancer Center

Liuniu Xiao

Huazhong University of Science and Technology Tongji Medical College

Caixia Zhou

Sun Yat-sen University Cancer Center

Yujing Fang

Sun Yat-sen University Cancer Center

Qingjian Ou

Sun Yat-sen University Cancer Center

Jiayi Qin

Sun Yat-sen University Cancer Center

Mengzhong Liu

Sun Yat-sen University Cancer Center

Zhizhong Pan

Sun Yat-sen University Cancer Center

Zhenlin Hou (✉ houlz@sysucc.org.cn)

Sun Yat-sen University Cancer Center

Research

Keywords: TRIM25, Oxaliplatin resistance, Colorectal Cancer

Posted Date: November 24th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-60545/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Cell Death & Disease on May 1st, 2021. See the published version at <https://doi.org/10.1038/s41419-021-03734-4>.

Abstract

Background

Resistance to chemotherapy remains the major cause of treatment failure in patients with colorectal cancer (CRC). Tripartite motif containing 25 (TRIM25), an E3-ubiquitin ligase, has been reported to play a vital role in tumorigenesis. The present study aimed to explore the function and mechanism of TRIM25 in regulating oxaliplatin resistance in colorectal cancer.

Methods

The expression of TRIM25 in colorectal cancer tissues was examined using publicly available datasets, immunohistochemistry, and western blotting. Further survival analysis was conducted using the Kaplan-Meier method. CCK8 assays, colony-formation assays, Annexin V-FITC /PI staining and xenograft tumor models were used to evaluate the sensitivity of CRC cells to oxaliplatin. Sphere-formation assays, RT-PCR and limiting dilution assays were used to evaluate the influence of TRIM25 on the stem cell properties of CRC cells. Co-immunoprecipitation, polyubiquitination assays and western blotting were used to determine the mechanism by which TRIM25 regulates EZH2.

Results

Patients with high expression of TRIM25 had a significantly higher recurrence rate (28.9% vs. 15.0%, $P = 0.012$) and worse disease-free survival ($P = 0.006$) than those with low TRIM25 expression. Downregulation of TRIM25 dramatically inhibited, while overexpression of TRIM25 increased, CRC cell survival after oxaliplatin treatment. In addition, TRIM25 promoted the stem cell properties of CRC cells both *in vitro* and *in vivo*. Importantly, we demonstrated that TRIM25 inhibited the binding of E3-ubiquitin ligase TRAF6 to EZH2, thus stabilizing and upregulating EZH2, and promoting oxaliplatin resistance.

Conclusions

Our study provided evidence that TRIM25 is a novel epigenetic regulator of oxaliplatin resistance. Targeting TRIM25 might be a promising strategy for CRC treatment.

Background

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth leading cause of cancer-related mortality [1]. Surgical resection plus oxaliplatin (OXA)-based chemotherapy is the most frequently used therapeutic strategy for patients with CRC [2]. However, cancer cells eventually develop chemoresistance, which is considered the major cause of treatment failure in patients with metastatic cancer and is a major limitation of the efficacy of chemotherapy drugs in clinical practice [3]. Thus, revealing the underlying mechanism and discovering new therapeutic targets are necessary to improve treatment outcomes for patients with CRC.

Cancer stem cells (CSCs) are a special cellular sub-population that exhibit self-renewing and tumorigenic capacities [4, 5]. In recent years, emerging evidence has suggested that the presence of CSCs is a key factor in tumor resistance to chemotherapeutic drugs [6]. The expression of stem cell markers, such as CD133 or CD44, is associated with chemoresistance [7, 8]. In glioblastoma, CD133-positive CSCs have demonstrated resistance to chemotherapy, by increasing the expression of the drug resistance gene BCRP1, the DNA mismatch repair gene MGMT, and some anti-apoptotic genes [7]. In hepatocellular carcinoma (HCC), up-regulation of CD44 has been proven to be related to resistance to anticancer drugs, including 5-Fluorouracil, cisplatin, and irinotecan [9]. Therefore, triggering CSCs to exit the stem-like state, which would result in increased response of cancer cells to chemotherapy, is a novel means of overcoming chemotherapy resistance.

Epigenetic regulation of transcriptional programs, including DNA methylation, non-coding RNAs, and histone posttranslational modifications (e.g., acetylation and methylation), is a key driver of the self-renewal capacity [10-12]. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is a critical component of the epigenetic polycomb repressive complex 2 (PRC2) and silences target genes via trimethylating histone H3 on lysine 27 (H3K27me3) [13]. Up-regulation of the H3K27me3 methyltransferase EZH2 has been observed in various cancers. EZH2 is associated with a high proliferation rate, aggressive tumor subtypes, and poor outcome of patients with cancer [14]. In addition, EZH2 is reported to contribute to chemotherapy response, and EZH2 inhibitors have been proven to reverse drug-resistance in cancers [2, 15]. Recent studies showed that EZH2 plays an essential role in maintaining CSC properties in multiple cancer types, including breast cancer, prostate cancer, and glioblastoma [16-18]. In the context of CRC, EZH2 has been proven to contribute to the CSC state by modulating key pathways such as Wnt/ β -catenin and Hedgehog signaling, where high EZH2 activity has been shown to designate the CSC population [15]. Therefore, EZH2 might be a promising target for cancer therapy.

Tripartite motif containing 25 (TRIM25) is a member of the tripartite motif (TRIM) family that functions in multiple RNA-dependent pathways [19]. Like a typical TRIM protein, TRIM25 consists of an N-terminal tripartite motif, or RBCC motif, and a C-terminal SPRY domain [20-22]. Accumulating evidence suggests that TRIM25 plays a key role in many physiological disorders, predominantly by regulating ubiquitination of its target protein. For example, TRIM25 is crucially involved in interferon signaling by mediating K63-linked polyubiquitination of RIG-1, which is important for host antiviral innate immunity [21]. Moreover, TRIM25 has recently been reported to be essential for tumorigenesis [23-26]. High expression of TRIM25 has been demonstrated in a variety of cancers, such as CRC, lung cancer, and breast cancer [23-25]. In hepatocellular carcinoma, TRIM25 promotes cancer cell survival and growth through targeting Keap1-Nrf2 pathway [26]. Despite extensive research on TRIM25 in cancer, the role of TRIM25 in regulating drug-resistance remains largely unknown.

In the present study, we revealed a previously unknown mechanism of oxaliplatin chemoresistance. We demonstrated that EZH2 is regulated by TRIM25 in CRC cells. TRIM25 inhibits the binding of TRAF6, an E3 ubiquitin ligase, to EZH2, which stabilizes EZH2 to promote oxaliplatin resistance. Our findings

suggest that TRIM25 is a novel epigenetic regulator, and targeting the TRIM25–EZH2 pathway might be a promising approach to CRC treatment.

Materials And Methods

Cell lines and cell culture

The CRC cell lines (SW48 and SW480) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured under conditions as recommended. All cell lines were authenticated using short tandem repeat (STR) fingerprinting and negatively tested for mycoplasma contamination before experiments.

Patients and tissue specimens

The formalin-fixed, paraffin-embedded CRC tissues (n = 223) were obtained between November 2007 and December 2012 at the Sun Yat-sen University Cancer Center. The patient characteristics are summarized in Supplementary Table 1. All patients were treated with a FOLFOX orXELOX regimen and followed up with regular surveillance at our hospital. Approvals from the ethical committee of Sun Yat-sen University Cancer Center and prior patient's consents were previously obtained for the use of these clinical specimens for research purpose.

Immunohistochemistry (IHC)

Immunohistochemistry analysis using paraffin-embedded CRC specimens was conducted following standard manufacturer's protocols as described previously. Primary antibodies anti-TRIM25 (Proteintech, 67314-1-Ig) and anti-EZH2 (Cell Signaling Technology, #5246) were used for IHC staining. IHC staining was evaluated by two independent gastrointestinal pathologists blinded to the patients' characteristics and clinical outcomes. Final IHC score was calculated based on both the extent and the intensity of staining. The staining extent that scored according to the percentage of positively stained cells ranged from 0 to 3 (0, 0–25%; 1, 25–50%; 2, 50–75%; and 3, 75–100%), while the intensity of staining was scored as 0 (negative staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). Specimens with the final scores ≥ 4 were defined as high expression, and specimens with the final scores < 4 were defined as low expression.

RNA interference

For knockdown of TRIM25, negative control (shNC) or target gene shRNAs were co-transfected into HEK293T with pHelper and pEnv. The virus was harvested from the transfected HEK293T cells, and the target cells were then infected with the viral supernatants for 2 consecutive days. Stable CRC cell lines were selected by treating with puromycin (2 $\mu\text{g}/\text{mL}$) for 10 days. Target sequences for shRNAs are shown in Supplementary Table 2.

Cell viability assay

CRC cells (5×10^3 cells/well) were seeded in 96-well plates and treated with corresponding processes. At the indicated time point, CCK8 was added into the wells and incubated with cells according to the product manual. Then the Thermomax microplate reader was used to measure the absorbance of each well at wavelength of 450 nm (A450).

Apoptosis assay

For cell apoptosis assay, colorectal cancer cells treated with oxaplatin were harvested and stained with Annexin V-FITC and propidiumiodide (PI) using an Annexin V-FITC/PI-staining kit (BD Pharmingen™, San Diego, CA, USA). After incubation at room temperature for 15 minutes, the cells were analyzed by flow cytometry.

Immunoprecipitation (IP) and Ubiquitination analysis

Cancer cells were washed with cold PBS and lysed in NP-40 lysis buffer at 4 °C. For EZH2 ubiquitination detection, twenty-four hours after transfection, cells were treated with the proteasome inhibitor MG132 (10 μM) for 6 hours and lysed with NP-40 lysis buffer supplemented with protease-inhibitor cocktail. Total cell lysates were incubated with the appropriate primary antibodies overnight and subsequently rotated with protein A/G beads for 2~4 h at 4 °C. The beads were then washed with NP-40 lysis buffer for three times, mixed with 2 × SDS sample buffer and boiled for 10 min. The co-precipitates were analyzed by immunoblotting analysis using a chemiluminescence method.

Xenograft tumor model

Male BABL/c nude mice (4–5 weeks old) were used to evaluate the clinical benefits of targeting TRIM25. For limiting dilution assay, indicated number of SW480 cells transfected with/without TRIM25 or shTRIM25 was subcutaneously injected to the left flank of each nude mouse. For tumors treated with oxaliplatin, TRIM25-overexpressing SW480 cells (5×10^5) treated with or without EZH2 inhibition were suspended in 100 μl PBS and subcutaneously injected to the left flank of each nude mouse. One week later, the mice were intraperitoneally injected with oxaliplatin (5 mg/kg, twice a week). Tumor growth curve was measured for 3 weeks and the volume of tumor was calculated as $\text{Length} \times \text{Width}^2 \times 1/2$. At the end of the study, we surgically removed the tumors from the sacrificed mice. The animal experiments were conducted according to the Animal Study Guidelines of the Ethics Committee of Sun Yat-Sen University.

Statistical analysis

Statistical analyses were performed using SPSS version 24.0 software. All data were presented as the mean ± SD. Statistical tests used in this study included the two-tailed Student's t test, χ^2 test and log-rank test. *P*-value < 0.05 was considered statistically significant.

Results

High expression of TRIM25 predicts recurrence in patients with CRC

We analyzed publicly available CRC mRNA expression profiles (GSE20842) obtained from the NCBI and found that the mRNA expression of TRIM25 is elevated in CRC tissues compared with that in normal tissues (Fig. 1a). To confirm our *in silico* observations, we detected TRIM25 protein levels in CRC samples. IHC staining showed that TRIM25 is present in both the cytoplasmic and nuclear regions of CRC cells. Further analysis demonstrated that the TRIM25 level in CRC tissues was significantly higher than that in adjacent normal tissues (Fig. 1b-c). To explore the potential role of TRIM25 in CRC therapy, we initially evaluated the TRIM25 level in 26 primary tumor tissues from patients with stage III CRC that were treated with OXA-based chemotherapy. The results showed that the TRIM25 level in OXA-resistant patients who developed recurrence during the follow-up period was significantly higher than that of patients who had no recurrence (Fig. 1d and Supplementary Figure S1a). We further analyzed TRIM25 expression in 223 paraffin-embedded human CRC specimens from patients who received Xelox or FOLFOX treatment after surgery (the patient characteristics are summarized in Supplementary Table 1). Representative IHC staining confirmed that TRIM25 levels were markedly increased in patients with CRC with tumor relapse (Fig. 1e). Patients with high TRIM25 levels demonstrated an observably higher recurrence rate than those with low TRIM25 levels (28.9% vs. 15.0%, $P = 0.012$, Fig. 1f and Table 1). Furthermore, compared with low TRIM25 levels, high TRIM25 levels were associated significantly with worse overall survival and disease-free survival ($P = 0.006$, Fig. 1g and Supplementary Figure S1b). Collectively, the above observations suggest that elevated TRIM25 levels contribute to the progression of CRC and are associated with the failure of OXA-based chemotherapy.

TRIM25 confers OXA resistance in CRC cells *in vitro*

We then examined whether TRIM25 was associated with resistance to OXA-based therapy in preclinical models. First, we established stable TRIM25 knockdown and overexpressing cells from the SW48 and SW480 CRC cell lines (Fig. 2a). A CCK8 assay showed that the IC50 values for OXA were decreased in the TRIM25-knockdown cells and increased in the TRIM25-overexpressing cells (Fig. 2b-c). Consistently, in the presence of OXA, TRIM25 knockdown dramatically inhibited, while TRIM25 overexpression enhanced, the colony-formation ability of SW48 and SW480 cells (Fig. 2d). Moreover, compared with the control cells, knockdown of TRIM25 resulted in significantly increased OXA-induced apoptosis of CRC cells, while overexpression of TRIM25 reduced OXA-induced apoptosis (Fig. 2e). Measurement of cleaved caspase 3 and cleaved PARP further confirmed that knockdown of TRIM25 increased OXA sensitivity and upregulation of TRIM25 conferred OXA resistance (Fig. 2f). Taken together, these results revealed that TRIM25 confers OXA resistance in CRC cells.

TRIM25 promotes stem cell properties of CRC cells

As reported previously, stemness is believed to be responsible for chemotherapy resistance, thus we hypothesized that TRIM25 is involved in regulating CRC stemness and performed experiments to test our hypothesis. We conducted the sphere formation assay, and found a decrease in sphere numbers and sizes in TRIM25 knockdown cells compared with the corresponding control cells, while overexpression of

TRIM25 enhanced the sphere formation ability of CRC cells (Fig. 3a). In addition, the expression of stem cell related molecules, such as EpCAM, SOX2, CD133, and CD44, in SW48 and SW480 cells was markedly reduced after TRIM25 inhibition, while their expression increased after TRIM25 overexpression (Fig. 3b and Supplementary Figure S2). Furthermore, limiting dilution analysis (LDA) *in vivo* confirmed the markedly reduced stem cell frequency in TRIM25 knockdown SW480 cells (Fig. 3c), with the formation of smaller and lighter tumors than those formed by the control SW480 cells (Fig. 3d-e). In addition, no visible tumors could be formed in nude mice when 1×10^4 TRIM25-knockdown SW480 cells were inoculated. These findings indicate the crucial role of TRIM25 in promoting the stem cell properties of CRC cells.

TRIM25 regulates EZH2 stability in CRC cells

As the catalytic subunit of PRC2, EZH2 plays an essential role in tumor progression. Previous studies revealed that targeting EZH2 inhibits CSC self-renewal and enhances the sensitivity of CRC to OXA [2, 15]. In the present study, we found that knockdown of TRIM25 decreased the protein level of EZH2 (Fig. 4a). However, there was no significant effect on EZH2 mRNA levels in both SW48 and SW480 cells (Fig. 4b), suggesting that TRIM25 might affect the stability of EZH2. To substantiate this assumption, we treated TRIM25-knockdown or control CRC cells with the protein synthesis inhibitor cycloheximide (CHX) and the proteasome inhibitor MG132. The results showed that knockdown of TRIM25 shortened the half-life of endogenous EZH2 protein in CRC cells after CHX treatment (Fig. 4c-d). The level of EZH2 was modestly increased in TRIM25-knockdown SW48 cells treated with MG132, and the same results were obtained in SW480 cells (Fig. 4e), implying that the ubiquitin–proteasome pathway might be involved in TRIM25-mediated stability of EZH2. Finally, we detected the EZH2 levels in the same cohort of CRC samples used for TRIM25 analysis using IHC staining and found that high EZH2 levels correlated significantly and positively with high TRIM25 levels (Fig. 4f). CRC samples with high TRIM25 levels showed a higher proportion of high EZH2 levels, whereas samples with low TRIM25 levels exhibited a lower proportion of high EZH2 levels (63.9% *vs.* 45.7%, $P = 0.009$, Fig. 4g). Patients with CRC with high levels of TRIM25 and EZH2 had the shortest overall survival ($P < 0.001$, Supplementary Figure S1c) and disease-free survival ($P < 0.001$, Fig. 4h) compared with patients with low TRIM25 or low EZH2 levels. Taken together, these observations suggest that TRIM25 regulates EZH2 levels in CRC cells by reducing the degradation of EZH2.

TRIM25 blocks TRAF6-mediated ubiquitination of EZH2

TRIM25 is an E3 ligase, therefore, we wondered if TRIM25 modulates EZH2 stability through the ubiquitin–proteasome pathway. First, we analyzed the interaction of TRIM25 with EZH2 in CRC cells. Using co-immunoprecipitation and western blotting, we verified the interaction between TRIM25 and EZH2 at both the exogenous and endogenous protein levels (Fig. 5a-b). Further immunofluorescence double staining demonstrated the co-localization of TRIM25 and EZH2 in the nuclei of SW480 cells (Supplementary Figure S3a). Then, we performed *in vivo* ubiquitination assays in HEK293T cells transfected with siTRIM25, Flag-EZH2, His-tagged ubiquitin wild-type (WT), or mutation plasmids (K48 or K63 mutants). As shown in Fig. 5c, knockdown of TRIM25 in HEK293T cells increased the poly-

ubiquitination of EZH2, indicating that EZH2 is not a substrate of TRIM25 E3 ligase. Interestingly, the enhanced EZH2 polyubiquitination by knockdown of TRIM25 was mainly extended through the K63-linkage instead of the K48-linkage. These findings were further validated in SW48 and SW480 cells (Supplementary Figure S3b).

TNF receptor associated factor 6 (TRAF6) is a member of the TNF receptor associated factor (TRAF) protein family, and functions as an E3 ubiquitin ligase and a scaffold protein. TRAF6 mediates the K63-linked ubiquitination of EZH2 in prostate cancer [27]. Thus, we speculated whether TRIM25 is involved in TRAF6-mediated ubiquitination of EZH2. First, we confirmed the co-localization of endogenous EZH2 and TRAF6 in the nuclei of SW480 cells (Supplementary Figure S3c). Then, we transfected siNC or siTRIM25 into SW480 cells. Western blotting analysis of the whole-cell extracts (WCE) showed that knockdown of TRIM25 had no significant effect on TRAF6 but decreased the level of EZH2 in SW480 cells, which was consistent with the results shown in Fig. 4a. A further immunoprecipitation assay showed that TRAF6 protein could be detected in EZH2 immunoprecipitate and knockdown of TRIM25 enhanced the interaction between EZH2 and TRAF6, implying that TRIM25 might interfere with TRAF6-mediated EZH2 ubiquitination (Fig. 5d). To confirm the role of TRIM25 in TRAF6-mediated EZH2 ubiquitination, we blocked TRAF6 in TRIM25-knockdown SW480 cells. Further co-immunoprecipitation and immunoblotting analysis showed that knockdown of TRIM25-induced EZH2 ubiquitination and degradation could be rescued using siTRAF6 (Fig. 5e-f). Taken together, these results suggest that TRIM25 stabilizes EZH2 by preventing TRAF6 binding to EZH2.

EZH2 is required for TRIM25-induced OXA-resistance in CRC both *in vitro* and *in vivo*

To further assess whether TRIM25 mediates OXA-resistance via EZH2, we blocked EZH2 in TRIM25-overexpressing cells using shRNA or an EZH2 inhibitor (UNC1999). Colony formation, CCK8 and Annexin V/PI apoptosis assays showed that inhibition of EZH2 significantly rescued the effect of TRIM25 overexpression on both the growth and anti-apoptotic capacity of CRC cells treated with OXA (Fig. 6a-c). Besides, the sphere formation ability of SW48 and SW480 cells overexpressing TRIM25 was markedly suppressed by EZH2 inhibition (Fig. 6d).

Moreover, a nude mouse xenograft model was used to evaluate the effect of EZH2 inhibition on TRIM25-induced OXA-resistance *in vivo*. Consistent with the *in vitro* findings, inhibition of EZH2 using shEZH2 or UNC1999 resulted in a significant reduction in tumor volume and weight when treated with OXA (Fig. 6e-f). Further TUNEL staining showed that inhibition of EZH2 resulted in more OXA-induced apoptosis compared with that in TRIM25-overexpressing cells *in vivo*, as demonstrated by a higher proportion of TUNEL positively stained cells after OXA treatment (Fig. 6g-h). Overall, EZH2 is essential for TRIM25-induced OXA-resistance in CRC, and inhibition of EZH2 is expected to overcome TRIM25-induced OXA-resistance in clinical practice.

Discussion

Oxaliplatin is one of the most common chemotherapeutic agents used to treat CRC. However, resistance to OXA remains a major barrier to satisfactory tumor regression in patients with CRC. In the present study, we demonstrated that TRIM25 was highly expressed in CRC tissues, and high expression of TRIM25 was associated significantly with OXA resistance in patients with CRC. Mechanistically, we clarified that TRIM25 upregulates EZH2 levels by reducing TRAF6-mediated EZH2 ubiquitination and degradation, thus promoting the stem cell properties of CRC cells. Our study revealed an important mechanism of OXA resistance and provided a promising strategy for CRC treatment.

TRIM25 is a member of the TRIM protein family, which represents the largest class of RING-containing E3 ubiquitin-ligases, and is involved in diverse cellular processes [28]. It was originally identified as an estrogen-responsive gene that is highly expressed in the breast, ovary, and uterus, and regulates various proteins involved in oncogenic signaling pathways. For example, in liver cancer, TRIM25 activates the Nrf2 signaling pathway and promotes tumor progression by interacting with and reducing the protein levels of Keap1 [26]. Ken-ichi et al. reported that TRIM25 enhanced prostate cancer cell growth and cell survival by modulating p53 signals via interaction with G3BP2 [28]. In the present study, we revealed that TRIM25 was a significant predictor of poor prognosis in patients with CRC treated with OXA, and high expression of TRIM25 predicted tumor recurrence, suggesting that TRIM25 is involved in OXA resistance. We then confirmed the important role of TRIM25 in sustaining CSC properties and inducing resistance of CRC cells to OXA-based treatment both *in vitro* and *in vivo*, and revealed a novel molecular mechanism based on the upregulation of EZH2 levels. These findings suggest that TRIM25 might be a potential therapeutic target for improving the response to OXA in patients with CRC.

Previous studies have identified the driving role of EZH2 in stem cell self-renewal. In CRC, EZH2 functions as a transcriptional repressor that downregulates IHH, a key gene responsible for normal colonocyte differentiation, resulting in an improved self-renewal capacity of CSCs [15]. In breast cancer, EZH2 increases NOTCH1 expression by directly binding to the NOTCH1 promoter and further promotes CSC properties or expands CSCs [17]. In addition to its canonical function via regulation of H3K27me3, EZH2 is reported to increase the self-renewal capacity of CSCs by binding to certain non-histone targets, such as STAT3, NF- κ B, and β -catenin [29-31]. Therefore, targeting EZH2 is thought to be a rational and innovative strategy to treat CRC. In our study, IHC and immunofluorescence staining showed that TRIM25 is present in both the cytoplasmic and nuclear regions of CRC cells, suggesting that TRIM25 functions in the cytoplasm and/or nuclei of CRC cells. Subsequently, we found that EZH2 was a major target of TRIM25 in CRC, in which TRIM25 upregulated the protein level of EZH2. However, knockdown or overexpression of TRIM25 had no influence on the mRNA expression of EZH2, suggesting that TRIM25 regulates EZH2 in the posttranslational level. Posttranslational modifications, such as phosphorylation and glycosylation, are thought to be the main factors affecting the stability and activity of EZH2. For example, phosphorylation at Serine 21 mediated by AKT suppresses the activity of EZH2, thereby decreasing H3K27me3 levels [32]. Glycosylation of EZH2 is required for its stability and enzymatic activity [33, 34]. Our study demonstrated the physical interaction and co-localization of EZH2 and TRIM25 in CRC cells, supporting the notion that TRIM25 might affect the function of EZH2 in CRC cells. We further confirmed that TRIM25 inhibited EZH2 ubiquitination, leading to increased stability of EZH2.

Taken together, these results indicated that EZH2 is not degraded by TRIM25 as an E3 ligase, and suggest a new function of TRIM25 as an inhibitor of ubiquitination.

The regulation of EZH2 ubiquitination is complex, and several E3 ligases, such as Smurf2, β -TrCP, FOXP3 and Praja1, have been reported to be involved in these processes [35-38]. TRAF6 is an adaptor protein and E3 ubiquitin ligase that belongs to the tumor necrosis factor receptor-associated factors (TRAFs) family, and plays a vital role in various solid tumors by activating multiple signaling pathways [39, 40]. A recent study showed that TRAF6 could catalyze K63-linked polyubiquitination of EZH2 and promote its proteasome-dependent degradation in prostate cancer [27]. Consistent with the results reported by Lu et al., we confirmed the co-localization of endogenous EZH2 and TRAF6 in the nuclei of SW480 cells, suggesting that TRAF6 might modulate EZH2 function in the same way in CRC cells. As shown in Fig. 5e-f, knockdown of TRAF6 reversed the elevated ubiquitination and repression of EZH2 mediated by TRIM25 silencing, implying that TRIM25 regulates EZH2 via TRAF6. This regulation could be explained by two possible mechanisms. One possibility is that TRIM25 directly inhibits the catalytic activity of TRAF6. The E3 ubiquitin ligase activity of TRAF6 requires autoubiquitination through Lys63 (K63)-linked ubiquitin chains, which depends on its ring finger domain. Indeed, Lee et al. reported that deletion of TRIM25 inhibits TRAF6 ubiquitination and TRAF6-mediated NK-kB activation [41]. The second possible mechanism is that TRIM25 might compete with TRAF6 to bind EZH2, which is supported by the data in the present study, showing that knockdown of TRIM25 promoted the interaction between TRAF6 and EZH2. These two mechanisms are not mutually exclusive, as suppression of TRAF6 activity might inhibit the binding of EZH2 to TRAF6. This is consistent with the previous reports that TRIM proteins can bind a protein to prevent its ubiquitination by another E3-ubiquitin ligase. For example, TRIM17 binds to BCL2A1 and prevents TRIM28-mediated ubiquitination and degradation of BCL2A1 in melanoma cells [42]. Besides, TRIM24 inhibits the degradation of dysbindin in cardiomyocytes in a similar manner [43].

In our cohort, patients with CRC with higher TRIM25 levels showed a worse response to OXA treatment and poor prognosis. Thus, TRIM25 could be a valuable biomarker to identify patients who could benefit from OXA treatment. In addition, our findings provide new insights into the chemoresistance of CRC cells. The future development of inhibitors against TRIM25 might be an excellent strategy for CRC management in clinical practice.

Conclusions

In summary, this study demonstrated that TRIM25 maintained the stem cell properties and promoted the resistance of CRC cells to OXA by inhibiting EZH2 ubiquitination via TRAF6. Our findings identified TRIM25-TRAF6-EZH2 as a novel pathway of CRC chemoresistance, highlighting the prospect of blocking this pathway to improve the prognosis of patients with CRC. Importantly, clinical evidence suggested a correlation between TRIM25 levels and the response of patients with CRC to OXA treatment. Our study contributes to a better understanding of OXA resistance and indicates that TRIM25 might be a new target for CRC treatment in the future.

Abbreviations

CRC: Colorectal cancer

CSC: Cancer stem cell

EZH2: Enhancer of zeste 2 polycomb repressive complex 2 subunit

TRAF6: TNF receptor associated factor 6

IHC: Immunohistochemistry

OXA: Oxaliplatin

CHX: Cycloheximide

RT-PCR: Real-time transcription-polymerase chain reaction

IP: Immunoprecipitation

Ub: Ubiquitin

Declarations

Ethics approval and consent to participate

Approvals from the ethical committee of Sun Yat-sen University Cancer Center and prior patient's consents were previously obtained for the use of these clinical specimens for research purpose.

The animal experiments were conducted according to the Animal Study Guidelines of the Ethics Committee of Sun Yat-Sen University.

Consent for publication

Not applicable.

Availability of data and materials

All data supporting our findings are included in the paper and its supplemental information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by China Postdoctoral Science Foundation (No. 2019M663289) and Natural Science Foundation of Guangdong Province (No. 2019A1515110144).

Author contributions

ZLH, ZZP and SZ designed the study. SZ and JHP contributed to the data acquisition and analysis. LNX constructed the expression plasmids and analyzed the data. YJF, QJO and JYQ analyzed public databases and participated in animal experiments. MZL and CXZ contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Author information

Sha Zhou, Jianhong Peng, and Liuniu Xiao contributed equally to this work.

Affiliations

Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Sha Zhou, Mengzhong Liu

Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Jianhong Peng, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Zhizhong Pan, Zhenlin Hou

Department of Intensive Care Unit of Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.

Liuniu Xiao

Corresponding authors

Correspondence to Zhizhong Pan or Zhenlin Hou.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. *CA Cancer J Clin.* 2015;65(2):87-108.

2. Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. *Mol Cancer Ther*. 2017;16:739-751.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* .2004;22:23-30.
4. Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. *BMB Rep*. 2017;50:117-125.
5. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer. *Nat Med*. 2014;20:29-36.
6. Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. *Clin Cancer Res*. 2014; 20:837-846.
7. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Mol Cancer*. 2006;5:67.
8. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. *Cancer Res*. 2001;61:5275-5283.
9. Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. *Int J Cancer*. 2015;136:E161-172.
10. Yoshida GJ. Emerging roles of Myc in stem cell biology and novel tumor therapies. *J Exp Clin Cancer Res*. 2018, 37:173.
11. Vincent A, Ouelkdite-Oumouchal A, Souidi M, Leclerc J, Neve B, Van Seuninghen I. Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. *World J Stem Cells*. 2019; 11:920-936.
12. Singh AK, Verma A, Singh A, Arya RK, Maheshwari S, Chaturvedi P, et al. Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells. *Epigenetics*. 2020:1-18.
13. Müller A, Dickmanns A, Resch C, Schäkel K, Hailfinger S, Dobbelsstein M, et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. *The Journal of clinical investigation*. *J Clin Invest*. 2020; 23:134217.
14. Cao W, Lee H. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. *Nat Commun*. 2020; 11:3675.
15. Lima-Fernandes E, Murison A, da Silva Medina T, Wang Y, Ma A, Leung C, et al. Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. *Nat Commun*. 2019;10:1436.

16. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. *Cancer Cell*. 2013;23:839-852.
17. Gonzalez ME, Moore HM, Li X, Toy KA, Huang W, Sabel MS, et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. *Proc Natl Acad Sci U S A*. 2014;111:3098-3103.
18. Gorodetska I, Lukiyanчук V, Peitzsch C. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. *Int J Cancer*. 2019; 145:2974-2985.
19. Sanchez JG, Sparrer KMJ, Chiang C, Reis RA, Chiang JJ, Zurenski MA, et al. TRIM25 Binds RNA to Modulate Cellular Anti-viral Defense. *J Mol Biol*. 2018;430:5280-5293.
20. Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, Cui S, et al. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. *Proc Natl Acad Sci U S A*. 2008;105:16743-16748.
21. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature*. 2007;446:916-920.
22. Zheng X, Wang X, Tu F, Wang Q, Fan Z, Gao G. TRIM25 Is Required for the Antiviral Activity of Zinc Finger Antiviral Protein. *J Virol*. 2017;91; e00088-17.
23. Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, et al. An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. *Cell Rep*. 2017;20:1623-1640.
24. Qin Y, Cui H, Zhang H. Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression. *Technol Cancer Res Treat*. 2016;15:707-715.
25. Sun N, Xue Y, Dai T, Li X, Zheng N. Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF- β signaling. *Biosci Rep*. 2017; 37:BSR20170805.
26. Liu Y, Tao S, Liao L, Li Y, Li H, Li Z, et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. *Nat Commun*. 2020;11:348.
27. Lu W, Liu S, Li B, Xie Y, Izban MG, Ballard BR, et al. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. *Oncogene*. 2017; 36:1364-1373.
28. Takayama KI, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. 2018;37:2165-2180.
29. Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. *Proc Natl Acad Sci U S A* . 2015;112:3985-90.
30. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, et al. Context-specific regulation of NF- κ B target gene expression by EZH2 in breast cancers. *Mol Cell*. 2011;43:798-810..
31. Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, et al. PAF and EZH2 induce Wnt/ β -catenin signaling hyperactivation. *Mol Cell*. 2013;52:193-205.

32. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. *Science*. 2005;310:306-310.
33. Lo PW, Shie JJ, Chen CH, Wu CY, Hsu TL, Wong CH. O-GlcNAcylation regulates the stability and enzymatic activity of the histone methyltransferase EZH2. *Proc Natl Acad Sci U S A*. 2018;115:7302-7307.
34. Chu CS, Lo PW, Yeh YH, Hsu PH, Peng SH, Teng YC, et al. O-GlcNAcylation regulates EZH2 protein stability and function. *Proc Natl Acad Sci U S A*. 2014;111:1355-1360.
35. Yu YL, Chou RH, Shyu WC, Hsieh SC, Wu CS, Chiang SY, et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. *EMBO Mol Med*. 2013;5:531-547.
36. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS. Oncogenic Y641 mutations in EZH2 prevent Jak2/ β -TrCP-mediated degradation. *Oncogene*. 2015;34:445-454.
37. Consalvi S, Brancaccio A, Dall'Agnese A, Puri PL, Palacios D. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38 α activation. *Nat Commun*. 2017;8:13956.
38. Shen Z, Chen L, Yang X, Zhao Y, Pier E, Zhang X, et al. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling? *Biochim Biophys Acta*. 2013;1833:2190-2200.
39. Min Y, Kim MJ, Lee S, Chun E, Lee KY. Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NF κ B activation and autophagy activation. *Autophagy*. 2018;14:1347-1358.
40. Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, et al. Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. *Autophagy*. 2014;10:257-268.
41. Lee NR, Kim HI, Choi MS, Yi CM, Inn KS. Regulation of MDA5-MAVS Antiviral Signaling Axis by TRIM25 through TRAF6-Mediated NF- κ B Activation. *Mol Cells*. 2015; 38:759-764.
42. Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. *Cell Death Differ*. 2019;26: 902-917.
43. Borlepawar A, Rangrez AY. TRIM24 protein promotes and TRIM32 protein inhibits cardiomyocyte hypertrophy via regulation of dysbindin protein levels. *J Biol Chem*. 2017;292:10180-10196.

Tables

Table 1
Association of TRIM25 expression with patient characteristics.

Characteristic	TRIM25 Expression		P-value
	Low	High	
Age (years)			0.245
<56	72 (51.4%)	36 (43.4%)	
≥56	68 (48.6%)	47 (56.6%)	
Sex			0.332
Male	75 (53.6%)	50 (60.2%)	
Female	65 (46.4%)	33 (39.8%)	
Tumor location			0.914
Right-sided	55 (39.3%)	32 (38.6%)	
Left-sided	85 (60.7%)	51 (61.4%)	
Primary tumor size			0.668
<4.5 cm	75 (53.6%)	42 (50.6%)	
≥4.5 cm	65(46.4%)	41 (49.4%)	
T stage			0.012
T1-2	66 (47.1%)	25 (30.1%)	
T3-4	74 (52.9%)	58 (69.9%)	
N stage			0.522
N1	92 (65.7%)	58 (69.9%)	
N2	48 (34.3%)	25 (30.1%)	
TNM stage			0.059
T1-3N1M0	47 (33.6%)	18 (21.7%)	
T4NanyM0 or TanyN2M0	93 (66.4%)	65 (78.3%)	
Recurrence			0.012
Yes	21 (15.0%)	24 (28.9%)	
No	119 (85.0%)	59 (71.1%)	

Figures

Figure 1

High expression of TRIM25 is associated with recurrence in colorectal cancer. a. Analysis of TRIM25 expression in CRC and adjacent normal tissues from publicly available GEO dataset (GSE20842), as assessed using a t-test. b. Representative IHC images of TRIM25 in colorectal tumor or normal tissues. Scale bar, 200 µm. c. IHC scores of TRIM25 levels in paired normal and CRC samples are shown as a symbol-line plot. Expression data for normal and tumor tissue from a given individual are linked with dashed lines. Differences were assessed using a paired two-tailed t-test. d. Western blotting analysis showing the level of TRIM25 in 26 primary tumor tissues from patients with stage III CRC who were treated with OXA-based chemotherapy, including 13 samples from patients who developed recurrence and 13 samples from patients who did not develop recurrence after surgical resection. e. Representative IHC images of TRIM25 in 223 CRC tissues with or without recurrence. Scale bar, 200 µm. f. Relationship between TRIM25 expression and CRC recurrence, as assessed using a χ^2 test. g. Comparison of disease-free survival between patients with high or low TRIM25 expression, as assessed using a log-rank test.

Figure 2

TRIM25 influences the sensitivity of CRC cells to oxaliplatin. a. Western blotting analysis of TRIM25 in SW48 and SW480 cells transfected with shTRIM25 or a TRIM25-expressing plasmid. GAPDH was used as the loading control. b-c. A CCK8 assay was used to measure the viability of the indicated cells treated with different concentrations of OXA for 48 h. d. Colony-formation ability (left panel: Representative images; right panel: Quantification of colony numbers) of the indicated cells treated with OXA (2 μ M). e.

Annexin V-FITC and PI staining showing apoptosis in the indicated CRC cells treated with OXA (30 μ M) for 48 h. Left panel: Representative images; right panel: Quantification of apoptotic cells. f. Western blotting analysis of cleaved caspase 3 and cleaved PARP in the indicated cells treated with or without OXA (30 μ M) for 48 h. Data are represented as the mean $\pm$ SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 3

TRIM25 promotes stem cell properties of CRC cells. a. Representative images (left panel) and quantification (right panel) of the in vitro sphere-formation assay of TRIM25-knockdown and TRIM25-overexpressing SW48 and SW480 cells. Scale bar, 200 μ m. Data are represented as the mean $\pm$ SD of three independent experiments. b. Relative mRNA expression of EpCAM, SOX2, CD133 and CD44 in TRIM25-knockdown or TRIM25-overexpressing SW48 and SW480 cells. Data are represented as the mean $\pm$ SD of three independent experiments. c. Limiting dilution data showing the stem cell frequency of the indicated group of SW480 cells from a tumorigenic mouse model. d. Growth curves of each group of tumors. Indicated numbers of SW480 cells were inoculated into the nude mice and tumor volumes were measured every four days. Data are represented as the mean $\pm$ SD. e. Each group of tumors were removed and weighted. Data represent as the mean $\pm$ SD. *P < 0.05, **P < 0.01, ***P < 0.001 for indicated comparison.

Figure 4

TRIM25 regulates EZH2 stability in CRC cells. a. Western blotting analysis of EZH2 in control and TRIM25-knockdown SW48 and SW480 cells. b. RT-PCR analysis of EZH2 mRNA in control and TRIM25-knockdown SW48 and SW480 cells. c. EZH2 protein levels in control and TRIM25-knockdown SW48 or SW480 cells were detected at the indicated time points after CHX (20 µg/mL) treatment. d. The relative level of EZH2 at each time point was normalized by the level of GAPDH. e. Western blotting showing the

effect of MG132 (10 μ M) on EZH2 levels in control and TRIM25-knockdown SW48 or SW480 cells. f. Representative IHC images of TRIM25 and EZH2 in two cases of CRC. Scale bar, 100 μ m. g. Relationship between TRIM25 expression and EZH2 expression in the same cohort of CRC samples, as assessed using the χ^2 test. h. Comparison of disease-free survival between patients with different TRIM25 and EZH2 expression patterns, as assessed using the log-rank test.

Figure 5

TRIM25 blocks TRAF6-mediated ubiquitination of EZH2. a. Endogenous interaction between TRIM25 and EZH2 was determined using co-immunoprecipitation with anti-TRIM25 or anti-EZH2 antibodies in SW480 cells. b. Exogenous interaction between TRIM25 and EZH2 was determined using co-immunoprecipitation with anti-Flag or anti-HA antibodies in HEK293T cells co-transfected with Flag-EZH2 and HA-TRIM25. c. Flag-EZH2, siTRIM25, His-tagged ubiquitin wild-type (WT) or mutation plasmids (K48 or K63 mutants) were transfected into HEK293T cells as the indicated combinations. Immunoprecipitation with anti-Flag antibodies was performed to detect the ubiquitination level of EZH2. d. Immunoprecipitation assay using IgG and anti-EZH2 antibodies in SW480 cells transfected with siNC or siTRIM25, followed by western blotting analysis with the indicated antibodies. WCE: Whole-cell extracts. e. Flag-EZH2, siTRIM25, siTRAF6, His-tagged ubiquitin wild-type (WT) were transfected into HEK293T cells as the indicated combinations. Immunoprecipitation with anti-Flag antibodies and western blotting with anti-His

antibodies were performed to detect the ubiquitination level of EZH2 under different conditions. f. Western blotting analysis of EZH2 in SW480 cells transfected with siTRIM25 and/or siTRAF6.

Figure 6

EZH2 is required for TRIM25-induced OXA-resistance in CRC. a. Colony-formation ability of the indicated cells treated with OXA (2 μ M) for 14 days. Left panel: Representative images; right panel: Quantification of colony number. b. CCK8 assay showing the IC₅₀ values for OXA in the indicated cells treated with

different concentrations of OXA or a combination with UNC1999 (1 μ M) for 48 h. c. Annexin V-FITC and PI staining showing apoptosis in the indicated CRC cells treated with OXA (30 μ M) or a combination with UNC1999 (5 μ M) for 48 h. Left panel: Representative images; right panel: Quantification of apoptotic cells. d. Representative images (left panel) and quantification (right panel) of the in vitro sphere-formation assay using the indicated CRC cells. Scale bar, 200 μ m. e. Growth curves and tumor volume of xenograft tumors derived from TRIM25-overexpressing SW480 cells treated with control (PBS), shEZH2 or UNC1999 (n = 6 mice for each group). All mice were intraperitoneally injected with OXA (5 mg/kg, twice a week) one week after CRC cells inoculation. f. Tumor weight of xenografts in each group. g. Apoptotic cells in paraffin-embedded tumor sections derived from each group of SW480 cells-bearing mice were visualized using TUNEL staining. h. Quantification of TUNEL-positive cells in the indicated group of tumor sections (n = 6). Data are represented as the mean $\pm$ SD. *P < 0.05, **P < 0.01, ***P < 0.001 for indicated comparison.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigures.docx](#)
- [SupplementaryTables.docx](#)